Beckman wins FDA nod for advanced test used in MI diagnosis

06/20/2013 | RTT News

The FDA has cleared Beckman Coulter, a unit of Danaher, to market its Access AccuTnI+3 troponin I test. The assay, which will run on the company's Access 2 immunoassay platform, has been shown in a clinical study to deliver precise as well as clinically sensitive and specific measurements to help doctors diagnose myocardial infarction.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC